(FM) Oncología
Departamento académico
![Foto de (FM) Oncología](/img/uploaded/1575D5546D141A10EB89AE669C8B8533.jpg)
![Foto de Novartis (Sweden)](/img/noimage_org.png)
Novartis (Sweden)
Täby, SueciaPublicaciones en colaboración con investigadores/as de Novartis (Sweden) (3)
2022
-
EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)
Future oncology (London, England), Vol. 18, Núm. 31, pp. 3481-3492
2019
-
Effectiveness of dabrafenib in the treatment of patients with braf v600-mutated metastatic melanoma in a named patient program
Melanoma Research, Vol. 29, Núm. 5, pp. 527-532
2013
-
Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2
Clinical Breast Cancer, Vol. 13, Núm. 6, pp. 421-432.e8